Extended Data Fig. 1: Functional antibody response to PCV13 and PPSV23.
Bubble plot showing the fold change in the antibody titers for individual serotypes in response to PCV13 (n = 19) a) and PPSV23 (n = 20) b). The size of the dots represents the magnitude of the fold change (FC) value, and the color indicates significant response (Log2 FC is > 3): blue for PCV13 and red for PPSV23. Donors are ordered from top to bottom according to the vaccine response Rank. On the left side, D0 SUM (sum of pre-vaccination OPA titers to 13 serotypes), D35 SUM (sum of 28 days post-vaccination OPA titers to 13 serotypes), the Strength, the Extent, the Rank and the maxRBA rank (sum of baseline adjusted fold changes to 13 serotypes) for each donor is displayed. c) Correlation between the Rank and the Strength, the Extent, the maxRBA for PCV13 (n = 19; top panel) and PPSV23 (n = 20; bottom panel). d) Correlation between the Rank and body mass index (BMI), frailty index (FI) and number of concomitant drugs. e) OPA titers (Log2) for individual serotypes showing the connecting lines between Pre and post-vaccination. f) Pre-vaccination and post-vaccination cumulative OPA titers (expressed as sum Log2) excluding serotype 6A. g) Correlation of Rank determined from all 23 serotypes and a subset of 13 serotypes present in the PCV13 in an independent cohort. The Pearson correlation metric was used to perform correlation analysis (c, d, and g) and p-value was generated using two-sided t-test. Boxplots display the median and IQR (25–75%), with whiskers representing the upper- and lower-quartile ±1.5 × IQR. The Wilcoxon matched-pairs signed-rank test (two-sided) was used in to compare the difference in mean between pre- and post-vaccination OPA titers for 13 serotypes (e, f) in PCV13 and PPSV23. The ‘n’ represents number of biological replicates.
